Soligenix, Inc. (SNGX)

Trade SNGX now with
12/18/2019 7:03:29 AM Soligenix To Get $850K In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
12/12/2019 7:18:26 AM Soligenix Initiates Phase 1C, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate The Safety Of RiVax
12/3/2019 7:08:33 AM Soligenix Completes Enrollment In Its Pivotal Phase 3 Clinical Trial Of SGX301 In Treatment Of Cutaneous T-cell Lymphoma
11/12/2019 7:15:13 AM Soligenix Q3 Net Loss $2.7 Mln Vs. Net Loss $1.9 Mln Last Year
9/16/2019 7:03:11 AM Soligenix Appoints Daniel Ring As VP Of Business Development And Strategic Planning
9/11/2019 7:02:19 AM Soligenix Appoints Jonathan Guarino As SVP And CFO
8/13/2019 7:23:52 AM Soligenix Q2 Basic Net Loss $2.1 Mln Or $0.12 Per Share
5/14/2019 7:07:51 AM Soligenix Q1 Basic Net Loss $1.6 Mln Or $0.09/shr Vs. Loss $2.4 Mln Or $0.27/shr Prior Year
4/23/2019 7:09:53 AM Soligenix Says Advances Development Of Heat Stable Ricin Toxin Vaccine-RiVax
4/4/2019 7:01:29 AM Soligenix Receives US Patent For Dusquetide Related Analogs
3/26/2019 7:07:56 AM Soligenix Says Actively Enrolling Patients In Phase 3 Clinical Trial Of SGX942
1/23/2019 6:02:06 AM Soligenix Secures European Patent For Dusquetide And Related Innate Defense Regulator Analogs